Sagimet Biosciences Inc. (SGMT) Stock

Sagimet Biosciences Inc. (SGMT) is a Healthcare stock trading at $10.25 (as of 2026-08-21), with a market capitalization of $544.42M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sagimet Biosciences Inc. is a biopharmaceutical company developing therapies that target fatty acid synthase (FASN) for conditions involving lipid metabolism dysfunction. Its pipeline includes Denifanstat for nonalcoholic steatohepatitis and acne and TVB-3567 for certain cancers.

Understand Sagimet Biosciences Inc.: how it makes money

Sagimet Biosciences develops FASN inhibitor therapeutics, led by Denifanstat for nonalcoholic steatohepatitis and acne, and TVB-3567 for certain cancers, with value driven by clinical trial results.

As a clinical-stage biopharmaceutical company with revenue of 0.0B, Sagimet’s profit model depends on whether its FASN inhibitor candidates, especially Denifanstat (NASH and acne) and TVB-3567 (cancers), generate sufficiently positive clinical outcomes to progress toward potential commercialization.

Business quality (Weak): A focused, clinical-stage pipeline around FASN inhibition, with specific trial outcome metrics provided for Denifanstat and meaningful ongoing R and D losses.

Bull case

  • Clinical fibrosis signals in NASH: Fibrosis improvement of at least one stage without worsening metabolic dysfunction-associated steatohepatitis was 30.0% (Intention-To-Treat), and 49.0% in F3 Modified Intention-To-Treat.
  • Observed acne efficacy signal: Percent Treatment Success (Investigator Global Assessment) was 33.2%.
  • Safety signals include relatively limited dry-eye and dry-skin incidence: Dry skin treatment-emergent adverse events occurred in 6.3% and dry eye in 5.9%.

Bear case

  • Early-stage and outcome uncertainty: The company is clinical-stage, so progress depends on ongoing and future trial results and regulatory review, not on established product revenue.
  • Potential for serious disease progression: Progression to cirrhosis (F4 Modified Intention-To-Treat) was 5.0%.
  • Large operating loss profile: Operating margin was -372.6% for the period ended 2023-09-30, reflecting substantial operating losses.
Valuation — source: SEC EDGAR (first-party)
Price$10.25
Market Cap$544.42M
Price / Book2.13
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.00M
Net Margin-1393.8%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($7.46M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid A. Happel
Employees14
CountryUS
IPO Date2023-07-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Aquestive Therapeutics, Inc. (AQST)
  • Shattuck Labs, Inc. (STTK)
  • Evolus, Inc. (EOLS)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Ovid Therapeutics Inc. (OVID)
  • NovaBridge Biosciences (NBP)
  • Prelude Therapeutics Incorporated (PRLD)
  • MapLight Therapeutics, Inc. (MPLT)
SGMT earnings history · SGMT institutional & insider holders · SGMT KPIs & operating metrics · SGMT financials · SGMT investor presentations & press releases · SGMT SEC filings · SGMT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.